Semaglutide is a long-acting analog of human glucagon-like peptide-1 (GLP-1). Three structural changes set it apart from the native hormone: an Aib substitution at position 8 that blocks DPP-4 degradation, an arginine substitution at position 34, and a C18 fatty diacid chain attached at lysine 26 that binds serum albumin. Together they extend the half-life from minutes to roughly one week.
Researchers use it to model GLP-1 receptor signaling in pancreatic beta cells, hypothalamic appetite circuits, and cardiovascular tissue. For a side-by-side look at how it compares with newer multi-agonists, see our semaglutide vs retatrutide vs tirzepatide guide.
Researchers can buy semaglutide here with confidence: each vial ships from US inventory with a COA matched to its lot number. Expand the section below for the full mechanism, published trial data, handling protocols, and frequently asked questions.
Detailed Mechanism of Action
Semaglutide binds the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, hypothalamic and hindbrain neurons, gastric smooth muscle, cardiomyocytes, and vascular endothelium. Receptor activation couples to the stimulatory G protein Gαs, raising intracellular cyclic AMP and activating protein kinase A and Epac2.
In beta cells this cascade amplifies glucose-dependent insulin exocytosis while leaving basal insulin release largely unchanged at low glucose. That glucose dependence is a defining feature of GLP-1 receptor agonists and one reason the class is so widely studied in metabolic research.
In the central nervous system, semaglutide reaches circumventricular regions such as the area postrema and the arcuate nucleus, where it activates POMC/CART neurons and indirectly inhibits NPY/AgRP neurons. Gabery and colleagues (JCI Insight, 2020) showed in rodents that the peptide engages a distributed network across the hypothalamus, brainstem, and septal nuclei rather than a single satiety center. Laboratories applying it to neuroscience work frequently map exactly these circuits.
Peripheral effects include slowed gastric emptying, reduced glucagon secretion from pancreatic alpha cells, and modulation of inflammatory signaling in adipose tissue and the vascular wall. The albumin-bound fatty diacid keeps plasma concentrations stable across a full week, which is why once-weekly protocols dominate the published literature.
Molecular identity matters for reproducibility. When you buy semaglutide from PSPeptides, mass spectrometry confirms the expected mass of approximately 4,113.6 Da, and HPLC confirms that at least 99% of the material is the intact 31-residue peptide rather than truncated or oxidized fragments.
Pharmacokinetics and Half-Life
The C18 diacid side chain gives semaglutide high affinity for serum albumin, so most circulating peptide travels bound rather than free. Albumin binding shields the molecule from renal clearance and enzymatic breakdown, producing a human half-life of approximately 165 hours, or about one week. Steady-state concentrations are reached after four to five weeks of weekly exposure.
This has practical consequences in the lab. Researchers running serum-containing cell assays should expect albumin in the medium to lower the free peptide fraction, shifting apparent potency. In rodent studies, the half-life is far shorter than in humans, which is why daily dosing schedules are common in preclinical designs. Our peptide half-life chart lists comparative values across the GLP-1 class.
Semaglutide is metabolized primarily through proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain. The main excretion routes are urine and feces, with only about 3% of a dose excreted unchanged in urine. Clearance was not meaningfully affected by renal or hepatic impairment in clinical studies, which simplifies interpretation of exposure data.
Published Research
Semaglutide is among the most extensively studied peptides in metabolic science. In the STEP 1 trial, Wilding et al. (NEJM, 2021) randomized 1,961 adults with overweight or obesity to 2.4 mg weekly or placebo for 68 weeks and reported a mean body-weight change of -14.9% versus -2.4%. Roughly one-third of treated participants lost 20% or more of baseline weight.
Cardiovascular data are equally robust. The SUSTAIN-6 trial by Marso et al. (NEJM, 2016) found a 26% relative reduction in major adverse cardiovascular events among 3,297 participants with type 2 diabetes. The later SELECT trial (Lincoff et al., NEJM, 2023) extended that finding to 17,604 people with obesity but no diabetes, reporting a 20% reduction in major cardiovascular events.
The STEP program added further detail. STEP 2 (Davies et al., Lancet, 2021) reported a -9.6% weight change in participants with type 2 diabetes, and STEP 4 (Rubino et al., JAMA, 2021) showed that withdrawing the peptide after 20 weeks led to substantial weight regain, underscoring that receptor engagement must be maintained for the effect to persist.
The molecule’s design history is documented by Lau and colleagues (Journal of Medicinal Chemistry, 2015), who described how the C18 diacid and linker were selected to maximize albumin affinity while preserving receptor potency. Researchers doing pharmacokinetic or receptor-binding work will find that paper the best starting reference.
More recent head-to-head studies, including the SURMOUNT-5 comparison with tirzepatide, position semaglutide as the established single-agonist reference point against which dual and triple agonists are measured. That reference status is one reason so many labs buy semaglutide as a control arm.
Semaglutide vs Alternatives
Before you buy semaglutide, it helps to understand where it sits relative to the newer incretin peptides. The table below compares the three most frequently studied compounds in this class.
| Feature | Semaglutide (This Product) | Tirzepatide | Retatrutide |
|---|
| Receptor targets | GLP-1 only | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Amino acid length | 31 | 39 | 39 |
| Molecular weight | 4,113.6 Da | 4,813.5 Da | ~4,731 Da |
| Human half-life | ~165 hours (7 days) | ~5 days | ~6 days |
| Peak trial weight reduction | -14.9% (STEP 1, 68 weeks) | -20.9% (SURMOUNT-1, 72 weeks) | -24.2% (phase 2, 48 weeks) |
| Development stage | Approved reference compound | Approved | Phase 3 trials |
| Depth of literature | Extensive, 10+ years | Growing | Early |
| Typical research role | Single-agonist control | Dual-agonist comparator | Next-generation triple agonist |
Tirzepatide is covered in depth in our tirzepatide research guide, and the retatrutide vs tirzepatide comparison breaks down the triple-agonist data. Liraglutide, the daily GLP-1 analog that preceded semaglutide, has a half-life of roughly 13 hours and produced about -8% weight change in the SCALE trial, which illustrates how much the albumin-binding modification changed the class.
Many researchers pair it with one of these compounds to run parallel arms, since a single-agonist baseline makes the incremental contribution of GIP or glucagon receptor activity easier to isolate.
Reconstitution & Handling
Each vial contains lyophilized semaglutide as a fine white powder. To reconstitute, allow the vial to reach room temperature, then slowly add bacteriostatic water down the inside wall of the vial rather than directly onto the powder. Swirl gently until the solution is clear; never shake, since agitation can shear the peptide backbone.
Common working concentrations for a 10mg vial: adding 1 mL of bacteriostatic water yields 10 mg/mL; adding 2 mL yields 5 mg/mL; adding 4 mL yields 2.5 mg/mL. At 2.5 mg/mL, each 0.1 mL drawn into a U-100 syringe (10 units) contains 250 mcg of peptide. Our peptide dosage calculator guide walks through converting any concentration into microgram-per-unit values.
Use bacteriostatic water containing 0.9% benzyl alcohol for multi-draw vials; sterile water without preservative is suitable only for single-use preparations. Details are in our explainer on what bacteriostatic water is. Researchers handling the compound for the first time should also read the full peptide reconstitution guide before opening the vial.
Storage & Stability
Lyophilized semaglutide is stable for 24 months or longer when stored at -20°C in the original sealed vial, and for several weeks at 2-8°C. Once reconstituted, keep the solution refrigerated at 2-8°C and use it within 28 days. Avoid repeated freeze-thaw cycles and protect the vial from direct light, which can oxidize sensitive residues such as tryptophan. Proper storage from the moment you buy semaglutide preserves the purity documented on the COA.
Labs holding the compound in quantity typically store sealed vials frozen and reconstitute one at a time. Vials ship at ambient temperature, which lyophilized peptide tolerates well for the duration of transit, but they should be refrigerated or frozen on arrival. Our peptide storage guide and degradation guide cover warning signs such as cloudiness, particulates, or discoloration.
Certificate of Analysis
Every lot ships with a batch-specific certificate of analysis, so you know exactly what you are receiving when you buy semaglutide from us. The COA reports HPLC purity (specification 99% or higher), mass spectrometry identity confirmation against the theoretical mass of semaglutide, physical appearance, and the lot number printed on your vial. Learn to interpret each field in our guide on how to read a peptide COA.
Independent testing is the single most important factor when you buy semaglutide for research. Purity below 98% introduces truncated sequences that can bind the GLP-1 receptor with different affinity, confounding dose-response data. PSPeptides relies on third-party results rather than in-house numbers alone so you can verify what is in the vial.
Third-party testing means the analytical laboratory has no financial stake in the result. Researchers sourcing from vendors that publish only in-house purity figures have no independent check, which is why PSPeptides ships every lot with externally generated data.
Research Protocol Considerations
For in vitro work, semaglutide is typically tested in GLP-1 receptor-expressing cell lines (for example, HEK293 or CHO cells transfected with human GLP-1R) using cAMP accumulation as the primary readout. EC50 values in the low picomolar range are expected for the intact peptide; a markedly right-shifted curve is an early sign of degraded material.
For in vivo rodent studies, diet-induced obese mice and rats are the most common models. Because the rodent half-life is much shorter than in humans, published protocols usually dose daily or every other day rather than weekly, and dose-ranging is generally performed on a per-kilogram basis. Vehicle controls should match the reconstitution buffer exactly.
Researchers designing dose-response work should prepare fresh dilutions from a single reconstituted stock, log the reconstitution date on the vial, and avoid drawing from a vial that has been open longer than four weeks. Our complete guide to peptides covers general laboratory practice for peptide handling.
Concentration can be verified in-house by UV absorbance at 280 nm, since the tryptophan and tyrosine residues in semaglutide absorb at that wavelength. Labs with HPLC access can also re-run purity on receipt and compare the chromatogram with the COA. When you buy semaglutide from PSPeptides, the COA gives you a reference trace to compare against.
Tolerability Data From Clinical Studies
Across the STEP and SUSTAIN programs, the most frequently reported effects were gastrointestinal: nausea, diarrhea, vomiting, and constipation, typically mild to moderate and most common during dose escalation. In STEP 1, nausea was reported by 44% of participants on the peptide versus 17% on placebo, and 7% discontinued because of adverse events compared with 3% on placebo.
These figures matter for study design because they informed the slow dose-escalation schedules used in nearly all subsequent trials. For a broader overview of what the literature reports across the peptide class, see our article on peptide side effects in published research. Labs modelling tolerability frequently replicate these escalation designs in animal models.
Combination and Comparative Study Design
Because semaglutide is the best-characterized single GLP-1 agonist, labs stocking it gain an anchor compound for a wide range of combination studies. Published and ongoing work pairs it with amylin analogs such as cagrilintide, with GIP receptor agonists, and with muscle-preserving agents to study lean-mass retention during weight reduction.
Researchers designing multi-arm experiments often order it together with tirzepatide or retatrutide from the same supplier so that purity specifications, reconstitution methods, and storage histories are consistent across arms. Our peptide stacking guide and best peptides for weight loss research overview describe the most common experimental pairings.
Why Researchers Buy Semaglutide From PSPeptides
- US Manufactured: Synthesized and lyophilized in the United States under controlled conditions.
- Third-Party Tested: Independent HPLC and mass spectrometry on every batch, with COAs you can match to your vial’s lot number.
- Fast Shipping: Free UPS 2nd Day Air on orders over $200, with same-day dispatch on orders placed before 2 PM EST.
- Flexible Payments: Credit cards, Afterpay, Klarna, Apple Pay, and Google Pay.
- 7-Day Support: Reach our team by email, phone, or text any day of the week.
Choosing where to buy semaglutide comes down to verification, consistency, and support. Our guide to choosing a research peptide supplier explains the questions every lab should ask before ordering, and our best peptide companies 2026 roundup shows how suppliers compare on testing transparency.
Frequently Asked Questions
Where can I buy semaglutide for laboratory research?
You can buy semaglutide directly from PSPeptides in single-vial quantities. Each order ships from US inventory with a batch-specific COA, and orders over $200 qualify for free UPS 2nd Day Air shipping.
What purity should I expect when I buy semaglutide?
Every PSPeptides lot is tested to 99% or higher purity by HPLC, with identity confirmed by mass spectrometry. The COA for your specific batch lists the exact figure recorded for that lot, so you are never relying on a generic claim.
How does research-grade semaglutide differ from prescription products?
Prescription semaglutide is a finished drug product formulated in a sterile pen for clinical use. Research-grade material is a lyophilized raw peptide intended for laboratory experiments, supplied without excipients or delivery devices. Our article on research peptides vs prescription peptides covers the distinction in detail.
How long does a vial last after I buy semaglutide?
Sealed lyophilized vials remain stable for two years or more at -20°C. After reconstitution with bacteriostatic water, plan to use the solution within 28 days and keep it refrigerated between uses.
Is it legal to buy semaglutide as a research peptide?
Research peptides are sold for in-vitro and laboratory use only and are not intended for human consumption. Regulations differ by jurisdiction, so review our overview of research peptide legality in 2026 before ordering.
What does the 1 vial option include?
Each order of Semaglutide (1 Vial) includes one sealed 10mg vial of lyophilized peptide with its batch COA. Bacteriostatic water, syringes, and other reconstitution supplies are sold separately and can be added to the same order.
How do I verify a batch after I buy semaglutide?
Match the lot number on your vial label to the lot number on the COA, then check that the HPLC purity and mass spectrometry results correspond to that same lot. If anything does not line up, contact support by email, phone, or text and we will send the matching document.
Related Resources
Ready to buy semaglutide for your next study? Select the 10mg vial above and check out in under a minute.
All PSPeptides products are sold exclusively for laboratory and research use. Not intended for human consumption.
Made & Shipped
